| Date | Title | Description |
| 18.08.2026 | Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer | Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer
Tue, Aug 18, 2026 10:35 CET Report this content
OSLO, Norway, 18 August 2026 – Lytix Biopharma ASA (“Lytix” or the “Com... |
| 06.08.2024 | Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update | -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; clinical data reports planned for 2024 and H1 2025 --
-- Enrolling 2L LBCL and prior CD19 relapsed LBCL patients based on CB-010 ANTLER Phase 1 ... |
| 01.04.2024 | Впервые в мире почку свиньи изменили генетически и пересадили человеку. Теперь их можно массово пересаживать... | Хирурги из США провели человеку трансплантацию почки, полученной из генетически модифицированной свиньи. СМИ сообщают, что данная операция является прорывом в области ксенотрансплантации, когда органы, клетки или ткани пересаживаются из одн... |
| 11.03.2024 | Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | -- 30th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 --
-- 1st patient dosed in CB-012 AMpLify Phase 1 trial for patients with r/r AML --
-- $372.4 million in c... |
| 11.03.2024 | Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - |
| 08.03.2024 | CAR T-Cell Therapy Market Set for Healthy Growth after COVID19 Pandemic Top Players Industry Trends and Forecast 2032 | CHICAGO, UNITED STATES, March 8, 2024 /EINPresswire.com/ -- Astute Analytica, a leading provider of market research and analysis, released its highly anticipated Market Analysis Report on the Global 𝐂𝐀𝐑 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭. This comprehen... |
| 05.03.2024 | Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting | - |
| 10.01.2024 | Caribou Biosciences Secures $155M to Push Company's Pipeline | - |
| 14.07.2023 | Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering | /EIN News/ -- BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of an upsized underwritten pub... |
| 13.07.2023 | Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering | - |
| 06.07.2023 | Caribou Biosciences Announces $25 Million Equity Investment from Pfizer | - |
| 09.05.2023 | Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update | /EIN News/ -- -- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion;
plan to report dose escalation data in H2 2023 --
-- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients at dose level 1 --
-- CB-012... |
| 09.03.2023 | Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update | /EIN News/ -- -- CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 --
-- CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 --
-- CB-012 IND-enabling studies initiated; IND submissi... |
| 17.11.2022 | Startup Cradle Lets You Design Custom Proteins By Just Typing In A Prompt | Cradle Team at their site in the Netherlands.Cradle |
| 18.10.2022 | Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022 | BERKELEY, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the presentation of a case report for long-term follow u... |
| 01.06.2022 | Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022 | BERKELEY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the company will host a webcast conference call to ... |
| 17.05.2022 | EXCLUSIVE: Anterra closes $260m Fund II, says quality of agrifoodtech opportunity ‘has increased exponentially’ | Agtech investment firm Anterra Capital has closed its second Global Food and Agriculture Technology Fund on $260 million. The fund will invest in entrepreneurs developing biotech and digital solutions across the agrifoodtech value chain, fr... |
| 12.05.2022 | Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy | -- 100% ORR (5 of 5 patients) and 80% CR (4 of 5 patients) achieved following 1 dose at the
initial dose level in patients with aggressive r/r B-NHL --
-- CB-010 is the 1st allogeneic CAR-T cell therapy to achieve 100% ORR (5 of 5 patients)... |
| 10.05.2022 | Pow.bio’s continuous fermentation technology might be the key to scaling up food production for a growing population | Fermentation, the process of breaking down sugars using the enzymes of microorganisms, is almost as old as civilization itself. The use of microbial cultures to preserve and improve the nutritional value of foods and produce alcoholic bever... |
| 03.05.2022 | Caribou Biosciences to Present at Upcoming Investor Conference | BERKELEY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chie... |
| 08.04.2022 | Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting | -- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity --
-- Data support an expected Investigational New Drug (IND) applicatio... |
| 21.03.2022 | Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update | -- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate for patients with r/r B-NHL --
-- 2022 submission of IND application planned for CB-011, an... |
| 07.02.2022 | Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference | BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chie... |
| 08.11.2021 | Caribou Biosciences Appoints Dara Richardson-Heron, M.D., to its Board of Directors and Ruhi Khan as Chief Business Officer | BERKELEY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointments of Dara Richardson-Heron, M.D., to its ... |
| 20.10.2021 | Caribou Biosciences to Present at Upcoming Investor Conferences | BERKELEY, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s President and Chie... |
| 02.09.2021 | Caribou Biosciences : Completed upsized initial public offering of common stock, raising $349.6 million in gross proceeds including full exercise of underwriters' option to purchase additional shares ... | Completed upsized initial public offering of common stock, raising$349.6 million in gross proceeds including full exercise of underwriters' option to purchase additional shares
ANTLER Phase 1 clinical trial of CB-010 in relapsed or refracto... |
| 26.07.2021 | Caribou raises $304M in one of gene editing’s most lucrative IPOs | From Biopharma Dive |
| 23.07.2021 | Caribou raises $304M in one of gene editing’s most lucrative IPOs | - |
| 04.03.2021 | Caribou Biosciences Raises $115M in Series C Funding | Caribou Biosciences, Inc., a Berkeley, Calif.-based clinical-stage CRISPR genome editing biotechnology company, closed a $115m Series C financing.
The round was co-led by new premier healthcare investors Farallon Capital Management, PFM Hea... |
| 03.03.2021 | Caribou nets $115M to boost CRISPR tech, advance off-the-shelf cell therapies | Original from: Fierce Biotech |
| 03.03.2021 | Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline | BERKELEY, Calif.–(BUSINESS WIRE)–Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the successful completion of an oversubscribed $115 million Series C financing. Proceeds from ... |
| 03.03.2021 | Caribou Biosciences Raises $115M Series C |
BERKELEY, CA, Caribou Biosciences, a genome editing biotechnology company, has completed an oversubscribed $115M Series C financing.
>> Click here for more funding data on Caribou Biosciences
>> To export Caribou Biosciences... |
| 09.10.2020 | Pontifax AgTech closes latest fund at $302m | Pontifax AgTech has closed its newest fund with $302 million raised, making it one of the world’s largest agrifood-dedicated investment vehicles to date.
The Los Angeles-based VC firm had initially targeted $250 million for its second fund,... |
| 12.08.2019 | Announcing the Disrupt SF 2019 agenda | Disrupt SF 2019 is set to be the biggest and best Disrupt yet. We’ve got a little something for everyone, including space chats with Lockheed Martin’s Marillyn Hewson and Blue Origin’s Bob Smith, a word from Snap CEO Evan Spiegel, a firesid... |
| 13.06.2018 | Tropic Biosciences Raises $10m Series A for Tropical CRISPR Tech | Tropic Biosciences, the UK-based startup using gene-editing technology including CRISPR to optimize coffee and banana crops, has raised $10 million in Series A funding from a global group of ag and biotech investors.
The oversubscribed roun... |
| 15.01.2018 | EXCLUSIVE: Biotech Dominates THRIVE Top 50 in AgTech List | Biotech and predictive analytics startups dominate the Salinas, CA-based THRIVE AgTech’s Top 50 list of agtech companies shaping the future of agriculture for 2018.
The largest technology category on last year’s list, “big data analytics,” ... |
| 28.07.2017 | Gene Editing Gets Public Market Approval as Calyxt Raises $64m IPO | Gene editing has caused a lot of excitement in agriculture technology circles for its potential to produce crops, and even animals, with improved characteristics. The technique, which enables undesirable traits — such as intolerance to heat... |
| 16.05.2017 | Caribou Bioscience’s CEO on CRISPR’s legal and ethical challenges | Caribou Bioscience co-founder and CEO Rachel Haurwitz joined us onstage at Disrupt this morning to help unpack some of the myriad complexities around her company’s pioneering work in the field of CRISPR biology. The gene editing tool has be... |
| 30.03.2017 | Will Consumer Acceptance Be The Challenge for CRISPR Technology in Agriculture? | Gene editing was a key topic discussed at this week’s World Agri-Tech Innovation Summit in San Francisco. It was particularly relevant as Benson Hill Biosystems, the plant biology, big data analytics and cloud computing startup, came out of... |
| 28.12.2016 | Best of 2016: AgFunder’s 10 Most Read Stories | It’s been a busy year for AgFunder as our member and subscriber base grew to over 25,000 and we posted nearly 500 articles on AgFunderNews.
Over 40 of these articles were written by our amazing network of expert contributors, and three of t... |
| 05.10.2016 | How Does Agtech Fit an Impact Investing Thesis? | Editor’s Note: I recently attended SOCAP, the largest conference for the impact investing community, and was excited to note a growing enthusiasm on the potential for food and agriculture technology to promote positive change in the world. ... |
| 05.10.2016 | Connecting the Dots: Trends in Crop Protection and Animal Health | Editor’s Note: Kevin Zussman is an agtech investor with Cultivian Sandbox, a venture capital firm that invests in food & agriculture technology startups. Cultivian Sandbox is a joint venture between Cultivian Ventures and Sandbox Ventur... |
| 09.06.2016 | How Big Data is Disrupting Agriculture from Biological Discovery to Farming Practices | Editor’s Note: Vonnie Estes is an agtech consultant with a particular focus on building biotech-focused startups. She has worked in business development roles at three of the big 6 — Monsanto, Syngenta, and DuPont — and is a known face in t... |
| 19.05.2016 | Fundings-in-Brief: Precision Ag Startups from Outside the US Raise Seed Funding, more | Avrio Capital Completes Three Investments
Avrio Capital has now deployed C$15 million of capital from its $110 million Fund III. The investments include poultry and swine health data analytics startup Intelia Technologies Inc. frozen fruit ... |
| 16.05.2016 | CRISPR Startup Caribou Biosciences Raises $30m Series B as Gene Editing for Ag Picks up Pace | Caribou Biosciences, a startup founded by Jennifer Doudna, the scientist largely attributed with the discovery of the CRISPR-Cas9 gene-editing tool, has raised $30 million in Series B funding.
Dutch food and agriculture technology venture f... |
| 16.05.2016 | Caribou Biosciences Completes $30M Series B Funding | Caribou Biosciences, Inc., a Berkeley, California-based developer of CRISPR-Cas technologies for genome engineering, completed a $30m Series B funding round.
Backers included new investors Anterra Capital, Heritage Group, Maverick Capital V... |
| 17.03.2016 | Monsanto’s Fraley on Staying Ahead in Agtech Innovation | Representatives from four of the world’s biggest agribusinesses gathered yesterday at the World Agri-Tech Investment Summit to discuss the value of collaboration and investment in agtech innovation. All agreed on the importance of partnersh... |
| 11.08.2015 | CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here are 6 more biotechs shaping CRISPR landscape | But that’s already turned quickly on its head.
Confidence is growing in the technology, as evidenced by the title of a fantastic Wired article: “Easy DNA Editing Will Remake the World. Buckle Up.” And the broader scientific community is now... |
| 23.06.2015 | Five conspicuous omissions from MIT Tech Review’s 50 smartest companies | …we did not have trouble finding big ideas. To make the list, a company must have truly innovative technology and a business model that is both practical and ambitious, with the result that it has set the agenda in its field over the past 1... |
| 13.05.2015 | The Genome Engineering Revolution | Ryan Clarke Contributor
More posts by this contributor
A Third Act For Biofuels
James Hyun Contributor
More posts by this contributor
A Third Act For Biofuels
Editor’s note: Ryan Clarke is a biochemistry PhD candidate with an interest in ge... |
| 02.04.2015 | Caribou Biosciences Closes $11M Series A Financing Round | Caribou Biosciences, a Berkeley, Calif.-based developer of technology-based solutions for cellular engineering and analysis, closed an $11m Series A financing round.
Backers included Fidelity Biosciences, Novartis, Mission Bay Capital, 5 Pr... |
| - | CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here are 6 more biotechs shaping CRISPR landscape | CRISPR/Cas9 gene editing has zoomed to the forefront of the biotech investment scape in the past year — punctuated this week by Editas Medicine‘s impressive $120 million fundraise. Looks like it’s no longer hype — there’s solid funding to p... |
| - | Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline | BERKELEY, Calif.--(BUSINESS WIRE)--Mar 3, 2021--
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the successful completion of an oversubscribed $115 million Series C financing... |
| - | Caribou Biosciences Secures $155M to Push Company's Pipeline | "CRISPR pioneer Caribou Biosciences secured $115 million in an oversubscribed Series C financing round that will be used to advance the company’s pipeline of wholly-owned allogeneic immune cell therapies for oncology and its next-gener... |
| - | Five conspicuous omissions from MIT Tech Review’s 50 smartest companies | We know who made the cut in the latest MIT Technology Review list of the 50 Smartest Companies of 2015.
But there were a few conspicuous omissions – take Theranos, for instance, or Alexion Pharmaceuticals – from the otherwise meaty list of ... |
